Smithkline Beckman Corporation

Smithkline Corporation

Other

Smithkline Beecham Corporation

Stephen T Ross

Lawrence I Kruse

Carl Kaiser

Eliot H Ohlstein

L Martin Brenner

John M Petta

James S Frazee

Thomas B Leonard

Joseph Robert Flisak

David L Ladd

A golf club that positions a golfer to establish a desired viewpoint of a golf ball when preparing to strike the golf ball with the golf club. The golf club includes an elongated shaft, a grip provided adjacent to a proximate end of the shaft that the golfer grips to hold the golf club while striking the golf ball during a golf swing, and a club head coupled adjacent to a distal end of the shaft and including a face exposed at a surface of the head for contacting the golf ball during the golf swing. A visual indicator is provided to the club head, wherein the visual indicator is observable by the golfer to indicate that the golfer is positioned in at least one of a predetermined longitudinal direction relative to the club head and a predetermined lateral direction relative to the club head to afford the golfer the desired viewpoint of the golf ball before striking the golf ball.

Golf club for golfer alignment

Putter

This invention provides (S)-7-&lsqb;(4,4&prime;-bipiperidin-1-yl)carbonyl&rsqb;-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid, hydrochloride, processes for its preparation and methods for its use.

Crystalline pharmaceutical product

Synthesis of acid addition salts of hydroxylamines

Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals.

Dopamine-.beta.-hydroxylase inhibitors

Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Intermediate to dopamine-.beta.-hydroxylase inhibitors

Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mannals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

2-(aminoalkylthio)imidazoles as dopamine-.beta.-hydroxylase inhibitors

Disclosed are novel substituted 3-aralkylimidazolines of the structure. ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.

1-aralkyl-2-mercaptoimidazolines as DBH inhibitors

Potent dopamine-.beta.-hydroxylase inhibitors having the Formula: ##STR1## which are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Trifluoro acetyl-cyano-aniline intermediates for

Disclosed are novel substituted 3-aralkyl-2-mercaptopyridines of the structure: ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.

3-aralkyl-2-mercaptoyridines as dopamine-.beta.-hydroxylase inhibitors

P-toluene-sulfonyl-oxy substituted pyridines

Compounds having the formula: ##STR1## which are ester prodrugs of potent dopamine-.beta.-hydroxylase inhibitors and thus are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmeceutical compositions including these compounds, and methods of using these compounds to inhibit dopamine-.beta.-hydroxylase activity in mammals.

Ester prodrugs of dopamine-.beta.-hydroxylase, inhibitors, composition

Imidazolethiol dopamine-beta-hydroxylase inhibitors

Potent dopamine-.beta.-hydroxylase inhibitors having the formula: ##STR1## which are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Growing community of inventors

Berwyn, PA, United States of America

Stephen T Ross